CPI-17 was consistently and highly overexpressed (4 of 4) in melanoma samples containing neither oncogenic BRAF V600E nor oncogenic NRas Q61K/R mutations; suggesting that Ras activity may primarily be driven via the CPI-17-ERM pathway in these cells. Here, BRAF is linked to melanoma.